-

I2Pure Hires Healthcare Industry Leader as Chief Executive Officer

Jeffrey Jochims Assumes Role of I2Pure CEO

ASHBURN, Va.--(BUSINESS WIRE)--Today, I2Pure announced the hiring of its new Chief Executive Officer, Jeffrey Jochims, effective November 1, 2023. Jeff succeeds I2Pure Founder Douglas Spitz, who is transitioning to the role of Executive Chair. Jochims also joins the I2Pure Board of Directors.

Jochims assumes this role following more than 25 years of leadership in the life sciences and healthcare industries, including long executive tenures at industry leaders Thermo Fisher Scientific and Owens & Minor. In addition, Jochims has deep experience in entrepreneurial start-ups as well as global life sciences and healthcare companies of all sizes. Businesses under Jochims’ influence have consistently delivered customer-centric operational excellence and market share gains.

“I2Pure has made tremendous progress since our formation only a few years ago. We’re elated to have someone of Jeff’s experience and capabilities join our company as Chief Executive Officer,” said Doug Spitz, I2Pure Founder. “Based on the incredible reception to our innovative iodine applications and the momentum that we’re building, the time arrived for I2Pure to bring on a seasoned executive that can lead us into the future. We’re humbled and proud that I2Pure has been able to attract and retain an executive leader of Jeff’s caliber. For more than two decades, Jeff has been highly successful in leading global businesses across the life sciences and healthcare industries,” continued Spitz.

“Rarely does a business present the kind of revolutionary and disruptive capabilities that I2Pure offers to healthcare and biosafety,” said Jochims. “This is truly a once-in-a-career opportunity to be part of something that can change healthcare and the world for decades into the future. Think of anesthesia, think of the polio vaccine. That is the kind of potential that I2Pure represents. It is exhilarating to take the helm of this incredible company and to work alongside its visionary founders to realize the potential of I2Pure,” he concluded.

With Jochims’ hiring, Doug Spitz transitions to the role of Executive Chair, succeeding Joseph Steinberg, who will remain on the I2Pure Board of Directors.

About I2Pure: I2Pure is a healthcare technology company dedicated to advancing the world of health and biosafety by preventing infections and disease through its patented, non-toxic molecular iodine platform. I2Pure’s mission is to prevent pathogenic threats to the world. Our technology can be used across virtually every facet of surgical and therapeutic interaction with human or animal tissue to prevent infection. The platform technology can be delivered via solutions, polymers and coatings and can be extended into medical devices, antisepsis, cosmetics, water safety, food safety and preservation, aquaculture and more.

For more information about I2Pure, visit https://www.i2pure.com.

Contacts

Abigail Moses
Abigail@i2pure.com

I2Pure

Details
Headquarters: Ashburn, VA
CEO: Jeff Jochims
Employees: 0-50
Organization: PRI

Release Summary
I2Pure announces the hiring of Jeff Jochims as their new Chief Executive Officer, effective November 1, 2023.
Release Versions

Contacts

Abigail Moses
Abigail@i2pure.com

Social Media Profiles
More News From I2Pure

Caracal and I2Pure Announce Collaboration to Bring New Disinfection and Antimicrobial Products to Market

ASHBURN, Va.--(BUSINESS WIRE)--Caracal Products & Services and I2Pure today announce a collaboration aimed at bringing new cutting-edge products to market. A certified Minority Business Enterprise and Tier 1 diversity spend supplier, Caracal is a solutions provider offering a wide variety of quality products and value add services to companies, government agencies and educational institutions of all sizes with particularly deep relationships in the healthcare, insurance and financial servic...

I2Pure Chief Scientist Receives ScholarGPS Highly Ranked Scholar Recognition

ASHBURN, Va.--(BUSINESS WIRE)--I2Pure is excited to announce that our Chief Scientist, Dr. Ilker Bayer, has been named a ‘Highly Ranked Scholar’ by ScholarGPS - one who ranks in .05% of 30 million scholars worldwide, based on his exceptional productivity, noteworthy impact and quality of scholarly work. Dr. Bayer joined I2Pure in January 2024 from the Istituto Italiano di Tecnologia (iit) where he had been a research scientist since 2010. Dr. Bayer received his Ph.D. degree in surface engineeri...

Magle Chemoswed and I2Pure Announce Joint Venture in Wound Care

ASHBURN, Va.--(BUSINESS WIRE)--In an ambitious move to transform wound care, Magle Chemoswed and I2Pure have unveiled a joint venture, marrying I2Pure's groundbreaking molecular iodine technology with Magle Chemoswed's innovative starch microspheres. This collaboration is poised to address critical patient needs and significantly enhance treatment outcomes in wound care. I2Pure, known for its dedication to infection prevention through non-toxic molecular iodine technology, joins forces with Mag...
Back to Newsroom